The registration process to participate as volunteers in Johnson & Johnson's Phase 3 clinical trials for a COVID-19 vaccine began on Thursday in Peru.
"We are happy to participate in this global effort to find an effective and safe COVID-19 vaccine. The Phase 3 study seeks to evaluate the safety and efficacy of the Johnson & Johnson's vaccine candidate for the prevention of COVID-19," said Dr. Jorge Gallardo, principal director of the Ensemble trial, in an interview with America Noticias TV show.
"This multinational study will be conducted in more than 180 research centers in eight countries, including Peru. It seeks to recruit more than 60,000 volunteers, of whom around 3,500 will be Peruvian," he explained.
The researchers in charge of this study are part of a Peruvian research consortium that brings together scientists with more than 20 years of experience in the field.
Said scientists come from four institutions: the Asociacion Civil Selva Amazonica (Amazon Rainforest Civil Association); the Asociacion Civil Impacta, Salud, y Educacion (Impact, Health, and Education Civil Association); the Asociacion Via Libre (Clear Path Association); and San Marcos University's Center for Biomedical and Environmental Technological Research.
Moreover, this consortium belongs to the COVID-19 Prevention Network, whose aim is to assess COVID-19 vaccine candidates —aimed at preventing its infection— in Phase 3 trials.
Who can participate?
The study is intended to include the participation of those most affected by the pandemic, including people with controlled comorbidities —such as diabetes and hypertension— as well as people over 60 years of age, in order to ensure that the vaccine will work for everyone.
Those wishing to participate can register online through the
trial website.
(END) KGR/LIT/RMB/MVB
Published: 11/12/2020